Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Richard E PratleyMansoor HusainIldiko LingvayThomas R PieberThomas MarkHans A SaevereidDaniel Vega MøllerBernard Zinmannull nullPublished in: Cardiovascular diabetology (2019)
In patients with T2D and high cardiovascular risk there were no treatment differences in terms of hHF. Prior HF was the strongest predictor of future hHF events, and there was an association between severe hypoglycemia and subsequent hHF. Further research should evaluate whether the risk of hHF can be modified by treatments aimed at reducing hypoglycemia. Trial Registration NCT01959529.
Keyphrases
- type diabetes
- glycemic control
- cardiovascular disease
- heart failure
- clinical trial
- study protocol
- acute heart failure
- early onset
- phase ii
- left ventricular
- current status
- insulin resistance
- adipose tissue
- metabolic syndrome
- cardiovascular risk factors
- atrial fibrillation
- weight loss
- coronary artery disease
- skeletal muscle
- smoking cessation